Lantheus (NASDAQ:LNTH) Releases Q4 2021 Earnings Guidance

Lantheus (NASDAQ:LNTH) issued an update on its fourth quarter 2021 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $0.150-$0.180 for the period, compared to the Thomson Reuters consensus estimate of $0.160. The company issued revenue guidance of $110 million-$115 million, compared to the consensus revenue estimate of $106.03 million.Lantheus also updated its FY 2021 guidance to $0.400-$0.430 EPS.

NASDAQ:LNTH traded down $0.22 during trading hours on Thursday, reaching $28.38. 316,142 shares of the stock were exchanged, compared to its average volume of 557,613. The company has a quick ratio of 2.18, a current ratio of 2.62 and a debt-to-equity ratio of 0.33. The firm has a 50 day simple moving average of $25.91 and a 200-day simple moving average of $25.41. The stock has a market capitalization of $1.92 billion, a P/E ratio of -55.65, a P/E/G ratio of 3.13 and a beta of 1.34. Lantheus has a 52 week low of $12.89 and a 52 week high of $31.60.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, November 4th. The medical equipment provider reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. The business had revenue of $102.10 million for the quarter, compared to analysts’ expectations of $97.13 million. Lantheus had a positive return on equity of 4.17% and a negative net margin of 8.84%. The business’s quarterly revenue was up 15.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.04 EPS. As a group, analysts expect that Lantheus will post 0.27 earnings per share for the current year.

A number of brokerages have recently weighed in on LNTH. Zacks Investment Research cut Lantheus from a buy rating to a hold rating in a research report on Saturday, November 13th. SVB Leerink restated an outperform rating on shares of Lantheus in a research report on Friday, October 22nd.

In other news, CFO Robert J. Jr. Marshall sold 4,502 shares of Lantheus stock in a transaction on Monday, October 18th. The stock was sold at an average price of $22.90, for a total transaction of $103,095.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CAO Andrea Sabens sold 1,242 shares of Lantheus stock in a transaction on Monday, November 15th. The shares were sold at an average price of $30.47, for a total value of $37,843.74. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 22,683 shares of company stock worth $626,113. 1.40% of the stock is owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC boosted its stake in shares of Lantheus by 162.0% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 6,563 shares of the medical equipment provider’s stock worth $169,000 after acquiring an additional 4,058 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of Lantheus by 79.5% during the 2nd quarter. Wells Fargo & Company MN now owns 63,953 shares of the medical equipment provider’s stock worth $1,767,000 after acquiring an additional 28,329 shares in the last quarter. Morgan Stanley boosted its stake in shares of Lantheus by 49.0% during the 2nd quarter. Morgan Stanley now owns 255,027 shares of the medical equipment provider’s stock worth $7,050,000 after acquiring an additional 83,817 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Lantheus by 0.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 620,082 shares of the medical equipment provider’s stock worth $15,923,000 after acquiring an additional 2,339 shares in the last quarter. 94.46% of the stock is owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes, and assist clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments.

Featured Story: Understanding and Trading Breakout Stocks

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.